Alcon Overview
- Year Founded
-
1945
- Status
-
Public
- Employees
-
25,942
- Stock Symbol
-
ALC
- Investments
-
32
- Share Price
-
$75.06
- (As of Thursday Closing)
Alcon General Information
Description
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Contact Information
Website
www.alcon.comCorporate Office
- Chemin de Blandonnet 8
- Vernier
- 1214 Geneva
- Switzerland
Corporate Office
- Chemin de Blandonnet 8
- Vernier
- 1214 Geneva
- Switzerland
Alcon Stock Performance
As of 19-Nov-2026, Alcon’s stock price is $75.06. Its current market cap is $36.1B with 480M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $75.06 | $74.06 | $61.45 - $88.50 | $36.1B | 480M | 1.07M | $1.37 |
Alcon Financials Summary
As of 30-Sep-2026, Alcon has a trailing 12-month revenue of $11B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 34,994,919 | 43,173,308 | 42,168,520 | 42,667,754 |
| Revenue | 10,984,000 | 10,401,000 | 9,911,000 | 9,455,000 |
| EBITDA | 2,665,000 | 2,625,000 | 2,592,000 | 2,197,000 |
| Net Income | 666,000 | 980,000 | 1,018,000 | 974,000 |
| Total Assets | 31,368,000 | 31,555,000 | 30,347,000 | 29,614,000 |
| Total Debt | 5,331,000 | 5,240,000 | 5,136,000 | 5,135,000 |
Alcon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alcon Comparisons
Industry
Financing
Details
Alcon Competitors (17)
One of Alcon’s 17 competitors is The Cooper Companies, a Corporation company based in San Ramon, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| The Cooper Companies | Corporation | San Ramon, CA | ||||
| Glaukos | Formerly VC-backed | Aliso Viejo, CA | ||||
| biolitec | Corporation | Vienna, Austria | ||||
| Stryker | Formerly VC-backed | Portage, MI | ||||
| Bausch + Lomb | Formerly PE-Backed | Bridgewater, NJ |
Alcon Patents
Alcon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260345390-A1 | Automated docking of an ophthalmic system to an eye | Pending | 05-May-2025 | ||
| WO-2026234495-A1 | Automated docking of an ophthalmic system to an eye | Pending | 05-May-2025 | ||
| US-20260349277-A1 | Generative artificial intelligence for manufacturing intraocular lenses | Pending | 05-May-2025 | ||
| WO-2026234490-A1 | Generative artificial intelligence for manufacturing intraocular lenses | Pending | 05-May-2025 | ||
| US-20260345228-A1 | Aspirating diathermy probe | Pending | 01-May-2025 | A61B18/1477 |
Alcon Signals
Alcon Investments & Acquisitions (32)
Alcon’s most recent deal was a Merger/Acquisition with Neurotech for . The deal was made on 20-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neurotech | 20-Oct-2026 | Merger/Acquisition | Drug Discovery | ||
| Lensar | 16-Mar-2026 | Merger/Acquisition | Other Devices and Supplies | ||
| LumiThera | 02-Sep-2025 | Merger/Acquisition | Other Devices and Supplies | ||
| Aurion Biotech | 24-Mar-2025 | Merger/Acquisition | Biotechnology | ||
| ViaLase | 03-Sep-2024 | Later Stage VC | Surgical Devices |
Alcon ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
16.23 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Alcon Exits (3)
Alcon’s most recent exit was on 22-Oct-2009 from Potentia Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Potentia Pharmaceuticals | 22-Oct-2009 | Completed |
|
||
| Optobionics | 01-Jun-2000 | Completed |
|
||
| MID Labs | 01-Jan-1985 | Merger/Acquisition | Completed |
Alcon Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aurion Biotech | Seattle, WA | 2021 | |
| LumiThera | Poulsbo, WA | 2013 | |
| BELKIN Vision | Yavne, Israel | 2013 | |
| Neurotech | Cumberland, RI | 2002 | |
| Kala Pharmaceuticals (EYSUVIS and INVELTYS) | Arlington, MA |
Alcon FAQs
-
When was Alcon founded?
Alcon was founded in 1945.
-
Where is Alcon headquartered?
Alcon is headquartered in Geneva, Switzerland.
-
What is the size of Alcon?
Alcon has 25,942 total employees.
-
What industry is Alcon in?
Alcon’s primary industry is Surgical Devices.
-
Is Alcon a private or public company?
Alcon is a Public company.
-
What is Alcon’s stock symbol?
The ticker symbol for Alcon is ALC.
-
What is the current stock price of Alcon?
As of 19-Nov-2026 the stock price of Alcon is $75.06.
-
What is the current market cap of Alcon?
The current market capitalization of Alcon is $36.1B.
-
What is Alcon’s current revenue?
The trailing twelve month revenue for Alcon is $11B.
-
Who are Alcon’s competitors?
The Cooper Companies, Glaukos, biolitec, Stryker, and Bausch + Lomb are some of the 17 competitors of Alcon.
-
What is Alcon’s annual earnings per share (EPS)?
Alcon’s EPS for 12 months was $1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process